|Bid||5.65 x N/A|
|Ask||5.72 x N/A|
|Day's Range||5.30 - 5.72|
|52 Week Range||5.00 - 12.62|
|Beta (5Y Monthly)||1.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
Aerpio (ARPO) unveils strategic alternatives after it announced top-line results from a phase II study of razuprotafib in glaucoma patients in December.
Novo Nordisk (NVO) files for a label expansion of Ozempic in the EU to include a new dose of 2.0 mg.
Aptose Biosciences (APTO) has been struggling lately, but the selling pressure may be coming to an end soon.